SAN CLEMENTE, Calif.–(BUSINESS WIRE)–#coraflex–Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, today announced the U.S. market launch of its next-generation Cora Flex® and Cora Force® Torqueable Microcatheters, now commercially available.
Designed for complex coronary interventions, the Cora Torqueable Microcatheters introduce enhancements focused on spinning freedom and torque transmission, supporting controlled navigation and lesion crossing in challenging anatomies.
The updated microcatheters incorporate refinements to hub design, shaft construction, and distal profile to improve handling, pushability, and trackability.
The Cora Flex Torqueable Microcatheter is designed to support navigation in tortuous vessels, septals, and microchannels, while the Cora Force Torqueable Microcatheter, featuring a metal tip, is engineered to provide additional pushability and tip force in more resistant, calcified, and fibrotic lesions.
The devices are built on Cora Tech™, a proprietary construction featuring a no-liner design with PTFE-coated coils to enable unrestricted torque rotation, combined with a stainless-steel braid intended to support controlled torque transmission and catheter stability. In addition to spinning freedom, the predictable torque transmission offers precise control, especially when navigating tortuous vessels.
“The new Cora Torqueable Microcatheters are truly next-generation devices that will become a standard in my daily practice,” said Garrett B. Wong, MD, FACC, FSCAI, Clinical Professor of Medicine at the UC Davis Medical Center, Sacramento, California. “Both versions deliver outstanding performance, especially spinning freedom. I can rotate the catheter without the risk of guidewire lock-up, which is a major benefit when crossing challenging anatomies.”
Dr. Wong was among the physicians who provided real-world procedural feedback during the iterative development of the Cora Torqueable Microcatheters.
“From an engineering perspective, we focused on optimizing rotational behavior, torque transmission, and overall handling characteristics,” said Outhit Bouasaysy, Vice President of Engineering at Reflow Medical. “These enhancements reflect direct physician input and our targeted approach to building endovascular solutions to advance the treatment of challenging coronary lesions.”
“The U.S. launch of the next-generation Cora platform represents an important step in expanding our coronary portfolio to support patients with coronary artery disease,” said Dejan Ilic, Vice President, Global Marketing at Reflow Medical.
Reflow Medical has recently expanded its presence in the coronary segment, including the presentation of first-in-human data from the DEEPER CORONARY study, evaluating the Spur® Elute Coronary Sirolimus-Eluting Retrievable Stent System for the treatment of coronary in-stent restenosis.
Reflow Medical is a global company that partners with leading physicians to develop innovative technologies addressing unmet clinical needs in the endovascular treatment of complex cardiovascular disease. The company’s portfolio includes coronary and peripheral microcatheters, crossing catheters, and its proprietary Retrievable Scaffold Therapy (RST) platform. The coronary Cora Catheters™ line is FDA approved. The peripheral product line includes Wingman™, Spex®, Spex LP, and Spur®, which have FDA clearance and CE Mark registration. Reflow Medical is headquartered in San Clemente, California.
Contacts
Jennifer Carlyle
[email protected]
949-481-0399
